Regulatory milestones

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) lost $3.74 (14%) to $22.42 on Wednesday after disclosing that FDA identified "deficiencies" in an sNDA for anemia drug Feraheme ferumoxytol that prevented the agency from discussing potential labeling or postmarket requirements with the company by Sept. 23, a target date set by the agency in March. FDA did not disclose the issues.